Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Apr;25(4):260-269.
doi: 10.1089/dia.2022.0479. Epub 2023 Feb 27.

Rollout of Closed-Loop Technology to Pregnant Women with Type 1 Diabetes: Healthcare Professionals' Views About Potential Challenges and Solutions

Affiliations
Clinical Trial

Rollout of Closed-Loop Technology to Pregnant Women with Type 1 Diabetes: Healthcare Professionals' Views About Potential Challenges and Solutions

David Rankin et al. Diabetes Technol Ther. 2023 Apr.

Abstract

Aims: To explore healthcare professionals' views about the training and support needed to rollout closed-loop technology to pregnant women with type 1 diabetes. Methods: We interviewed (n = 19) healthcare professionals who supported pregnant women using CamAPS FX closed-loop during the Automated insulin Delivery Amongst Pregnant women with Type 1 diabetes (AiDAPT) trial. Data were analyzed descriptively. An online workshop involving (n = 15) trial team members was used to inform recommendations. Ethics approvals were obtained in conjunction with those for the wider trial. Results: Interviewees expressed enthusiasm for a national rollout of closed-loop, but anticipated various challenges, some specific to use during pregnancy. These included variations in insulin pump and continuous glucose monitoring expertise and difficulties embedding and retaining key skills, due to the relatively small numbers of pregnant women using closed-loop. Inexperienced staff also highlighted difficulties interpreting data downloads. To support rollout, interviewees recommended providing expert initial advice training, delivered by device manufacturers together with online training resources and specific checklists for different systems. They also highlighted a need for 24 h technical support, especially when supporting technology naive women after first transitioning onto closed-loop in early pregnancy. They further recommended providing case-based meetings and mentorship for inexperienced colleagues, including support interpreting data downloads. Interviewees were optimistic that if healthcare professionals received training and support, their long-term workloads could be reduced because closed-loop lessened women's need for glycemic management input, especially in later pregnancy. Conclusions: Interviewees identified challenges and opportunities to rolling-out closed-loop and provided practical suggestions to upskill inexperienced staff supporting pregnant women using closed-loop. A key priority will be to determine how best to develop mentorship services to support inexperienced staff delivering closed-loop. Clinical Trials Registration: NCT04938557.

Keywords: Closed-loop system; Continuous glucose monitoring; Healthcare professional; Pregnancy; Qualitative research; Type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

A.B. reports: receiving speaker fees from Novo Nordisk, Sanofi, Dexcom, and Abbott Diabetes Care. C.B. reports: receiving speaker fees from ABCD Diabetes Technology Network. S.H. reports: receiving speaker and advisory board fees from Dexcom, Medtronic, Sanofi, and Ypsomed; and being Director of ASK Diabetes Ltd., he receives consulting/training fees from CamDiab Ltd. E.M.S. reports: receiving honoraria for talks given to Abbott Diabetes Care and Eli-Lilly. R.H. reports: receiving speaker honoraria from Eli Lilly, Dexcom, and Novo Nordisk; receiving license and/or consultancy fees from B. Braun and Abbott Diabetes Care; patents related to closed-loop; and being Director at CamDiab. H.R.M. reports: sitting on the Medtronic European Scientific Advisory Board and receiving speaker honoraria from Dexcom, Abbott Diabetes Care, Medtronic, and Novo Nordisk. D.R., J.L., R.I.H., B.K., K.B.-K., C.C., A.R.D., K.F.H., T.T.M.L., R.S.L., D.R.M., A.M., G.R., R.M.R., and S.L.W. have no conflicts of interest to declare.

References

    1. Battelino T, Danne T, Bergenstal RM, et al. : Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593–1603. - PMC - PubMed
    1. Feig DS, Donovan LE, Corcoy R, et al. : Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 2017;390:2347–2359. - PMC - PubMed
    1. Murphy HR, Bell R, Cartwright C, et al. : Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study. Diabetologia 2017;60:1668–1677. - PMC - PubMed
    1. Garcia-Patterson A, Gich I, Amini SB, et al. : Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction. Diabetologia 2010;53:446–451. - PubMed
    1. NICE: National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period (NG3) 2015 (amended 2020). https://www.nice.org.uk/guidance/ng3/resources/diabetes-in-pregnancy-man... (accessed October 31, 22). - PubMed

Publication types

Associated data

Grants and funding